Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vilaine, J.P.
Right arrow Articles by Peglion, J.L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Vilaine, J.P.
Right arrow Articles by Peglion, J.L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Procoralan, a new selective If current inhibitor

J.P. Vilaine*,1, C. Thollon1, N. Villenueve1 and J.L. Peglion2

a Division Pathologies Cardiaques et Vasculaires, Institut de Recherches Servier, Suresnes, France
b Division Chimie B, Institut de Recherches Servier, Suresnes, France

* J. P. Vilaine, MD, Institut de Recherches Servier, Division pathologies cardiaques et vasculaires, 11 rue des Moulineaux, 92150 Suresnes, France.

Abstract

Procoralan (S 16257-2) is a selective inhibitor of the pacemaker If current. It reduces in vitro the spontaneous beating rate of the sinus node by slowing the diastolic depolarization slope of the action potential. It induces in vivo a selective and prolonged reduction in heart rate, both at rest and during exercise. It preserves myocardial contractility, atrioventricular conduction and ventricular repolarization duration. Procoralan has a similar anti-ischaemic activity as a beta-adrenergic blocker but it limits to a greater extent the ischaemic myocardial dysfunction. Procoralan should have major therapeutic benefits in ischaemic heart disease, in particular when associated with heart failure.

Key Words: Heart rate • current • ivabradine • Procoralan • sinus node

References

  1. Matsuzaki M, Patritti J, Tajimi T, et al. Effects of ß-blockade on regional myocardial flow and function during exercise. Am J Physiol. 1984;56:H52–H60
  2. Guth BD, Heusch G, Steitelberger R, Ross J Jr.. Mechanism of beneficial effect of ß-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res. 1987;60:738–746[Abstract/Free Full Text]
  3. Guth BD, Indolfi C, Heusch G, et al. Mechanism of benefit in the ischemic myocardium due to heart rate reduction. Basic Res Cardiol. 1990;85:157–166
  4. Guth BD, Heusch G, Steitelberger R, Ross J Jr.. Elimination of exercise-induced regional myocardial dysfunction by a bradycardic agent in dogs with chronic coronary artery stenosis. Circulation. 1987;75:661–669[Abstract/Free Full Text]
  5. Indolfi C, Guth BD, Miura T, et al. Mechanism of improved ischemic regional dysfunction by bradycardia. Studies on UL-FS 49 in swine. Circulation. 1989;80:1365–1369
  6. Dyer AR, Persky V, Stamler J, et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol. 1980;112:736–749[Abstract/Free Full Text]
  7. Friedman GD, Klatsky AL, Siegelaub AB. Predictors of sudden cardiac death. Circulation. 1975;52:164–169
  8. Hjalmarson A, Gilpin EA, Kjekshus JK, et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol. 1990;65:547–553[CrossRef][Web of Science][Medline]
  9. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic follow-up study. Am Heart J. 1991;121:172–177[CrossRef][Web of Science][Medline]
  10. Kannel WB, Kannel C, Paffengarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987;113:1489–1494[CrossRef][Web of Science][Medline]
  11. Wilhelmsen L, Berglund G, Elmfeldt D, et al. The multifactor primary prevention trial in Goteborg, Sweden. Eur Heart J. 1986;7:279–288[Abstract/Free Full Text]
  12. Norwegian Multicenter GroupGundersen T, Grottum P, Pedersen T, Kjekshus JK. Effect of timolol on mortality and reinfarction after acute myocardial infarction: prognostic importance of heart rate at rest. Am J Cardiol. 1986;58:20–25[CrossRef][Web of Science][Medline]
  13. Kjekshus J. Importance of heart rate in determining beta-blocker efficacy in acute and long-term myocardial infarction intervention trials. Am J Cardiol. 1986;57:43F–49F[CrossRef][Medline]
  14. Frishman WH, Furberg CD, Friedewald WT. ß-adrenergic blockade in survivors of acute myocardial infarction. N Engl J Med. 1984;310:830–837[Web of Science][Medline]
  15. The Multicenter Diltiazem Postinfarction Trial Research Group. Effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:85–92
  16. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II — DAVIT II). Am J Cardiol. 1990;66:779–785[CrossRef][Web of Science][Medline]
  17. Packer M, Bristow MR, Cohn JN, et al. The effect of cervedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349–1355[Abstract/Free Full Text]
  18. CIBIS-II Investigators and Committees. A randomised trial of ß-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765–1773[Medline]
  19. Nul DR, Doval HC, Grancelli HO, et al. Heart rate is marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol. 1997;29:1199–1205[Abstract]
  20. Peglion JL, Vian J, Thollon C, et al. S 16257, a novel sinoatrial node modulator: potent bradycardic activity with improved specificity [abstract]. Can J Physiol Pharmacol. 1994;72(Suppl 1):95
  21. Thollon C, Cambarrat C, Vian J, et al. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol. 1994;112:37–42[Web of Science][Medline]
  22. Thollon C, Bibouard JP, Cambarrat C, et al. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. Eur J Pharmacol. 1997;339:43–51[CrossRef][Web of Science][Medline]
  23. Carmeliet E. Electrophysiologic and voltage clamp analysis of the effects of Sotalol on isolated cardiac muscle and Purkinje fibers. J Pharmacol Exp Ther. 1985;232:817–825[Abstract/Free Full Text]
  24. Abrahamsson C, Duker G, Lundberg C, Carlsson L. Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel lk blocking drugs, UK-68, 768 (Dofetilide) and E-4031. Cardiovasc Res. 1993;27:861–867[Abstract/Free Full Text]
  25. Irisawa H, Brown HF, Giles W. Cardiac pacemaking in the sinoatrial node. Physiol Rev. 1993;73:197–227[Free Full Text]
  26. Brown HF, DiFrancesco D, Noble SJ. How does adrenaline accelerate the heart? Nature. 1979;280:235–236[CrossRef][Medline]
  27. DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Ann Rev Physiol. 1993;55:451–467
  28. DiFrancesco D. The onset and autonomic regulation of cardiac pacemaker activity: relevance of the current. Cardiovasc Res. 1995;29:449–456[CrossRef][Web of Science][Medline]
  29. DiFrancesco D. The pacemaker current (If) plays an important role in regulating SA node pacemaker activity. Cardiovasc Res. 1995;30:307–308[CrossRef][Web of Science][Medline]
  30. Bois P, Bescond J, Renaudon B, Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol. 1996;118:1051–1057[Web of Science][Medline]
  31. DiFrancesco D, Mangoni M. Modulation of single hyperpolarization-activated channels (If) by cAMP in the rabbit sino-atrial node. J Physiol. 1994;474:473–482[Abstract/Free Full Text]
  32. DiFrancesco D, Ferroni A, Mazzanti M, Tromba C. Properties of the hyperpolarizing-activated current (if) in cells isolated from the rabbit sino-atrial node. J Physiol (Lond). 1986;377:61–88[Abstract/Free Full Text]
  33. DiFrancesco D, Tromba C. Acetylcholine inhibits activation of the cardiac pacemaker current, if. Pflügers Arch. 1987;410:139–142[CrossRef][Web of Science][Medline]
  34. Simon L, Ghaleh B, Puybasset L, et al. Coronary and haemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275:659–666[Abstract/Free Full Text]
  35. Berdeaux A, Drieu La Rochelle C, Richard V, Giudicelli JF. Opposed responses of large and small coronary arteries to propranolol during exercise in dogs. Am J Physiol. 1991;261:H265–H270
  36. Drieu La Rochelle C, Giudicelli JF, Berdeaux A. Differential effects of celiprolol and atenolol on large epicardial coronary arteries in conscious dogs at rest and during exercise. J Cardiovasc Pharmacol. 1993;22:15–21[Web of Science][Medline]
  37. Vigué B, Ghaleh B, Giudicelli JF, Berdeaux A. {alpha}1 and {alpha}2-adrenergic control of large and small coronary arteries during exercise in conscious dogs under ß-blockade. Fund Clin Pharmacol. 1993;7:520–527
  38. Vilaine JP, Bidouard JP, Lesage L, et al. Anti-ischemic effects of ivabradine, a selective heart rate reducing agent, in exercise-induced myocardial ischemia in pigs. J Cardiovasc Pharmacol (in press).

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
P. Colin, B. Ghaleh, X. Monnet, L. Hittinger, and A. Berdeaux
Effect of Graded Heart Rate Reduction with Ivabradine on Myocardial Oxygen Consumption and Diastolic Time in Exercising Dogs
J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 236 - 240.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vilaine, J.P.
Right arrow Articles by Peglion, J.L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Vilaine, J.P.
Right arrow Articles by Peglion, J.L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?